Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome - a retrospective analysis of the Polish Adult Leukemia Group

被引：0

作者：

Golos, Aleksandra ^{[1
]}

Mikulski, Damian ^{[2
]}

Grobelska-Kowalik, Monika ^{[3
]}

Madry, Krzysztof ^{[4
]}

Lis, Karol ^{[4
]}

Sobas, Marta ^{[5
]}

Ozanska, Agnieszka ^{[5
]}

Czemerska, Magdalena ^{[1
]}

Hawrylecka, Dorota ^{[6
]}

Stelmach-Goldys, Agnieszka ^{[7
]}

Chromik, Karolina ^{[8
]}

Pula, Bartosz ^{[9
]}

Sobczyk-Kruszelnicka, Malgorzata ^{[10
]}

Gora-Tybor, Joanna ^{[1
]}

机构：

[1] Med Univ Lodz, Dept Hematol, Lodz, Poland

[2] Med Univ Lodz, Dept Biostat & Translat Med, Lodz, Poland

[3] Prov Multispecialized Oncol & Trauma Ctr, Hematooncol Dept, Lodz, Poland

[4] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, Warsaw, Poland

[5] Wroclaw Med Univ, Dept & Clin Hematol Blood Neoplasms & Bone Marrow, Wroclaw, Poland

[6] Hosp Brzozow, Dept Hematol, Brzozow, Poland

[7] Holy Cross Canc Ctr, Dept Hematol, Kielce, Poland

[8] Med Univ Silesia, Sch Med Katowice, Dept Hematol & Bone Marrow Transplantat, Katowice, Poland

[9] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland

[10] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Bone Marrow Transplantat & Oncohematol, Warsaw, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2024年 / 28卷 / 02期

关键词：

lymphoma; therapy-related myeloid neoplasm; therapy-related myelodysplastic syndrome; therapy- related acute myeloid leukemia; WORLD-HEALTH-ORGANIZATION; NON-HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; SECONDARY LEUKEMIA; NEOPLASMS; TRANSPLANTATION; RISK; CLASSIFICATION; LENALIDOMIDE; CHEMOTHERAPY;

D O I：

10.5114/wo.2024.141727

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Enhancing lymphoma outcomes increases the risk of therapy-related neoplasms such as acute myeloid leukemia (t-AML) and myelodysplastic syndrome (t-MDS). Material and methods: Our study, conducted at seven Polish hematology centers between 2011 and 2018, explores clinical features, outcomes, and prognostic factors of t-AML and t-MDS arising after initial lymphoid neoplasms. Results: The analysis included 57 patients of median age 65 with t-MDS (n n = 38) and t-AML (n n = 19). The median time to the onset of t-MDS/ AML was 58.7 months. The median overall survival (OS) was 16.1 months. The presence of unfavorable cytogenetics and molecular risk factors (HR 2.88, 95% CI: 1.29-6.42, p = 0.009), hemoglobin level (HR 0.79, 95% CI: 0.65-0.95, p = 0.01) and platelets (HR 0.99, 95% CI: 0.99-0.9996, p = 0.03) were independent prognostic factors influencing OS. Therapy- related myelodysplastic syndrome/ acute myeloid leukemia after lymphoma treatment is associated with a dismal prognosis mainly due to poor cytogenetic risk. Conclusions: Anemia and thrombocytopenia may indicate more severe impairment of bone marrow function, resulting in further inferior treatment outcomes.

引用

页码：149 / 157

页数：9

共 38 条

[1] Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis [J].